Xeris Pharmaceuticals Inc (XERS) — Financial Flexibility Index
Xeris Pharmaceuticals Inc (XERS) has a Financial Flexibility Index of 0.02x as of June 2026. Free cash flow of $8.47 Million (operating CF $8.26 Million minus capex $209.00K) represents 0% of total liabilities ($421.64 Million). Check total reinvestment intensity of Xeris Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Xeris Pharmaceuticals Inc Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Xeris Pharmaceuticals Inc across 10 annual periods. For the full cash flow conversion analysis, see XERS operating cash flow.
Annual Financial Flexibility Index for Xeris Pharmaceuticals Inc (2016–2025)
Year-by-year free cash flow to debt coverage for Xeris Pharmaceuticals Inc. Explore how well can Xeris Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.08x | $29.32 Million | $28.63 Million | $369.84 Million | ▲ +177.4% |
| 2024 | -0.10x | $-36.11 Million | $-36.98 Million | $352.68 Million | ▲ +24.6% |
| 2023 | -0.14x | $-44.76 Million | $-47.02 Million | $329.38 Million | ▲ +60.3% |
| 2022 | -0.34x | $-102.37 Million | $-102.89 Million | $299.33 Million | ▲ +24.3% |
| 2021 | -0.45x | $-94.45 Million | $-95.53 Million | $209.13 Million | ▲ +46.7% |
| 2020 | -0.85x | $-80.18 Million | $-80.56 Million | $94.55 Million | ▲ +22.3% |
| 2019 | -1.09x | $-103.24 Million | $-104.35 Million | $94.55 Million | ▲ +11.0% |
| 2018 | -1.23x | $-54.77 Million | $-56.28 Million | $44.62 Million | ▼ -426.7% |
| 2017 | -0.23x | $-23.96 Million | $-24.66 Million | $102.83 Million | ▲ +5.0% |
| 2016 | -0.25x | $-16.05 Million | $-16.09 Million | $65.47 Million | — |